DAYTON, Ohio, June 3, 2008 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies, announced today that the United States Patent and Trademark Office (USPTO) has provided notice that it will award the Company U.S. patent No. 7,387,793 on June 17, 2008, entitled “Modified Release Dosage Forms of Skeletal Muscle Relaxants.” The Company will also be awarded a Patent Term Adjustment of an additional 470 days, providing Eurand with coverage on Amrix(r) until at least February 26, 2025.
